The market is expected to witness a paradigm shift toward the adoption of extended half-life therapies owing to the increased advantages such as long-lasting action, and reduced need for repeated dosing of medications. Therefore, extended half-life therapies are expected to affect the volume shipments of factor VIII units particularly in developed economies.

PART 01: Executive summary

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Highlights

PART 05: Deficiency overview

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview

Five forces analysis

PART 08: Market segmentation by type of disease

application

Global hemophilia A drugs market

Global hemophilia A inhibitors treatment market

Global von Willebrand disease treatment market

PART 09: Market segmentation by type of therapy

Recombinant therapies

Plasma-derived therapies

PART 10: Market segmentation by type of disease

management

Prophylaxis

On-demand therapy

Inhibitor therapy

PART 11: Geographical segmentation

Factor VIII deficiency treatment market in Americas

Factor VIII deficiency treatment market in EMEA

Factor VIII deficiency treatment market in APAC

PART 12: Market drivers

Increasing adoption of prophylactic drugs

Paradigm shift toward the development of drugs with

extended half-life

Large patient pool driving the shipments of factor VIII

units

PART 13: Impact of drivers

PART 14: Market challenges

Low diagnosis rate affecting the market growth

High entry barriers

Cost-intensive complex treatment

PART 15: Impact of drivers and challenges

PART 16: Market trends

Increase in technological innovations

Development of gene therapy products

Expansion initiatives of vendors fueling the market

growth

Increasing investments of vendors to improve the

production capability

PART 17: Vendor landscape

Competitive scenario

PART 18: Key vendor analysis

Bayer HealthCare

CSL

Grifols

Novo Nordisk

Pfizer

Shire

Other prominent vendors

PART 19: Appendix

List of abbreviation

PART 20: Explore Technavio